News

Military champion has Prytime Medical ready for prime time

Prytime Medical Devices Inc. CEO David Spencer said his company is poised to take its flagship technology ...

Texas Biomed taps new research leadership to help craft aggressive game plan

Joanne Turner has joined Texas Biomedical Research Institute as its new vice president of research. COURTESY ...

Industry Publications

The Mission

The Mission is published by the University of Texas Health Science Center.

UTSA Discovery

UTSA Discovery is published annually for the Office of the Vice President for Research by the Office ...

News
Bluegrass Vascular Technologies Gets $4.5 Million in Funding and Moves to San Antonio
July 30, 2014

 

Dr. John Gurley, founder of Bluegrass Vascular

By Laura Lorek, Silicon Hills News

Medical technology startup Bluegrass Vascular Technologies has closed on $4.5 million in funding.

Targeted Technology Fund II, a San Antonio-based venture capital fund that invests in early stage life sciences companies, led the Series A investment.

As part of the deal, Bluegrass Vascular will move its headquarters to San Antonio. The company, founded in 2011, will move from Lexington, Kentucky.

The company plans to use the funds for regulatory approval submissions for the Surfacer Inside-Out Access Catheter System, manufacturing and to obtain CE Mark for its device.

"The Surfacer System is a propriety system that allows physicians to gain venous access using a novel "inside-out" approach.

"The Surfacer System addresses a significant unmet clinical need in the vascular access market by allowing physicians to gain access through a previously occluded vein," Alan Dean, senior managing director of Targeted Technology Fund II and Bluegrass Vascular Director, said in a news release.

"With a growing market awareness of central venous occlusion and interest in maintaining access, we believe Bluegrass Vascular is well positioned to have a strong presence in the dialysis and chemotherapy markets and is a valued addition to our investment portfolio."

The product addresses a problem suffered by more than two million patients worldwide who develop blocked veins during medical treatment.

"After all central veins become compromised, patients must resort to invasive surgical techniques to gain or maintain CVA," according to a news release. "The Surfacer System maintains access in an occluded vein, halting the progression to invasive surgery and downstream health risks associated with poor circulation, using a less risky inside-out approach."

 

Stay informed. Subscribe to BioMed SA news alerts.